Genenta Science (NASDAQ:GNTA) Shares Down 0.6% – Should You Sell?

Shares of Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA) fell 0.6% during trading on Wednesday . The stock traded as low as $1.64 and last traded at $1.64. Approximately 61,336 shares were traded during trading, a decline of 48% from the average daily volume of 118,827 shares. The stock had previously closed at $1.65.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings lowered Genenta Science from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, July 10th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, Genenta Science currently has a consensus rating of “Sell”.

Genenta Science Trading Down 0.6%

The company has a 50 day moving average of $1.47 and a 200-day moving average of $1.11. The company has a debt-to-equity ratio of 0.35, a quick ratio of 14.16 and a current ratio of 14.16.

Institutional Trading of Genenta Science

Institutional investors and hedge funds have recently modified their holdings of the business. SmartHarvest Portfolios LLC acquired a new position in shares of Genenta Science in the 4th quarter valued at about $26,000. Citadel Advisors LLC bought a new stake in shares of Genenta Science during the 3rd quarter valued at about $41,000. Alyeska Investment Group L.P. acquired a new stake in Genenta Science during the fourth quarter worth about $328,000. Norges Bank acquired a new stake in Genenta Science during the fourth quarter worth about $337,000. Finally, Weiss Asset Management LP bought a new position in Genenta Science in the fourth quarter worth about $480,000. 15.13% of the stock is owned by institutional investors and hedge funds.

About Genenta Science

Genenta Science (NASDAQ: GNTA) is a clinical-stage biotechnology company focused on the development of in vivo hematopoietic stem cell (HSC) gene therapies for the treatment of solid tumors. The company’s proprietary platform enables the transplantation of genetically engineered HSCs that home to tumor sites and continuously deliver immunomodulatory agents. By harnessing the patient’s own stem cells, Genenta aims to establish a sustained, localized anti-tumor immune response with the potential to overcome limitations of traditional cytokine or antibody therapies.

Genenta’s lead product candidate, Temferon, consists of autologous HSCs engineered to produce interferon-alpha under the control of a tumor microenvironment–activated promoter.